Aortic Valve Diseases – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Aortic Valve Diseases – Drugs In Development, 2024 report and make more profitable business decisions.
Aortic Valve Disease (AVD) is a type of valve disease where hearts aortic valve does not work properly. Aortic valve controls the flow of blood from heart to all the body parts. When there is a damage to the aortic valve blood flow is affected. The 2 main aortic valve diseases are aortic stenosis and aortic regurgitation. In aortic stenosis blood flow is restricted as the valve gets narrowed while in regurgitation leakage of blood back to the heart occurs. It can be congenital or can develop later in life. Aging, underlying diseases, aortic dissection, trauma, senile aortic calcification, bicuspid aortic valve are the common causes and symptoms are chest pain, SOB, dizziness, irregular heartbeat, loss of appetite, weight gain. Diagnosed by 2D echo, ECG, chest X-ray, MRI and sometimes cardiac catherization done. Mild cases of AVD does not need any treatment. Mild to moderate require symptomatic treatment and preventive measures. Surgical procedures to replace the damaged aortic valve.
The Aortic Valve Diseases drugs in development market research report provide comprehensive information on the therapeutics under development for Aortic Valve Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aortic Valve Diseases and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Aortic Valve Diseases | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 12 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Aortic Valve Diseases therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Aortic Valve Diseases pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Aortic Valve Diseases treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abcentra LLCNovartis AG
Rancho Santa Fe Bio Inc
REDNVIA Co Ltd
Spark Biopharma Inc
Tyred Co Ltd
University of Ulsan
Vifor Pharma Management Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Aortic Valve Diseases reports